- Drugs
- Friday, 22 May 2020
Hikma receives FDA approval for its generic Vascepa®
Hikma Pharmaceuticals PLC (Hikma), the multinational generic pharmaceutical company, has announced that its wholly owned U.S. subsidiary Hikma Pharmaceuticals USA Inc. has received approval from the US Food and Drug Administration (FDA) for its Icosapent Ethyl Capsules, 1 gm, the generic equivalent to Vascepa®1.
In March 2020, the United States District Court for the District of Nevada invalidated six key Vascepa® patents owned by Amarin. The District Court decision is currently being appealed.
Brian Hoffmann, President of Generics said, "The approval for our generic version of Vascepa® is an important milestone towards bringing this product to market. This approval demonstrates the strength of our regulatory capabilities and our commitment to provide patients and healthcare providers in the US with the high-quality medicines they need."
| Enquiries | |
| Hikma Pharmaceuticals PLC | |
| Susan Ringdal | +44 (0)20 7399 2760/ +44 7776 477050 |
| EVP, Strategic Planning and Global Affairs | |
| Steve Weiss | +1 732 720 2830/ +1 732 788 8279 |
| David Belian | +1 732 720 2814/+1 848 254 4875 |
| US Communications and Public Affairs |
Related Industry Updates
Europe Small Molecule Drug Delivery Market: Industry Overview, Trends and Growth Opportunities Forecasted Till 2027
Aug 25, 2020
Neurotrope and Metuchen Pharmaceuticals Announce Merger Agreement to Form Petros Pharmaceuticals, a Men's Health Company
May 19, 2020
CaaMTech Collaborates With National Institutes of Health to Research Psychedelics
May 08, 2020
Asia and Africa Lateral Flow Assay Market is expected to reach US$ 2,159.62 million by 2028
May 23, 2023
Europe Pharmaceutical Continuous Manufacturing Market 2027 Growth Factors, Opportunities, Ongoing Trends with Top Companies Like Fette Compacting, KORSCH AG, LEISTRITZ AG, ALEXANDERWERK AG, Hovione
Dec 02, 2020
Epilepsy Market is expected to reach US$ 10.7 billion by 2030
Feb 14, 2024
Anti-Viral Therapies Market is expected to reach US$ 82,928.76 million in 2028
Jan 16, 2023
Follow us on
